Former Chief Medical Officer · X4 Pharmaceuticals, Inc (XFOR)

E Kelley

FY2019 is the first fiscal year CompBrief holds for E Kelley as a named executive officer of X4 Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$969,951

Salary $280,968Stock awards $0

3rd of 4 named executive officers at X4 Pharmaceuticals by FY2019 total.

4 named officers on file for X4 Pharmaceuticals, FY2019

E Kelley’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how X4 Pharmaceuticals’s whole pay program stands against its peers

  • X4 Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on XFOR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2020 (DEF 14A).

Free

Get E Kelley’s full pay file as a PDF — free

More than this page: up to 10 years of E Kelley’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

E Kelley compensation by year

X4 Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as X4 Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019
Salary$280,968
Bonus$0
Stock awards$0
Option awards$566,374
Non-equity incentive$121,005
Pension and deferred compensation$0
All other$1,604
Total$969,951

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: X4 Pharmaceuticals, Inc DEF 14A filed April 28, 2020, accession 0001193125-20-123073, and prior-year filings. Open the filing on EDGAR.

How this page was built: the X4 Pharmaceuticals, Inc filed document, accession 0001193125-20-123073. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2020.

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
Option37,170—$20.30

Per the Outstanding Equity Awards at Fiscal Year-End table in X4 Pharmaceuticals, Inc's FY2019 proxy; value at the fiscal year-end close, as the company printed it.

X4 Pharmaceuticals’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Paula RaganPresident, Chief Executive Officer, Corporate Secretary and Director$2,497,851
Michael GrayFormer President, Chief Executive Officer and Chief Financial Officer$1,139,822
E Kelley · this pageFormer Chief Medical Officer$969,951
Adam MostafaChief Financial Officer and Treasurer$866,231

The full X4 Pharmaceuticals compensation record

free company brief

This page is one person within X4 Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are X4 Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

E Kelley's compensation dossier · One-time report. No refunds.